(NASDAQ: AXSM) Axsome Therapeutics's forecast annual revenue growth rate of 54.72% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.64%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.92%.
Axsome Therapeutics's revenue in 2026 is $561,263,000.On average, 22 Wall Street analysts forecast AXSM's revenue for 2026 to be $51,824,193,920, with the lowest AXSM revenue forecast at $41,331,811,157, and the highest AXSM revenue forecast at $67,099,223,840. On average, 18 Wall Street analysts forecast AXSM's revenue for 2027 to be $80,004,859,680, with the lowest AXSM revenue forecast at $57,571,234,880, and the highest AXSM revenue forecast at $101,026,930,560.
In 2028, AXSM is forecast to generate $104,001,276,320 in revenue, with the lowest revenue forecast at $73,854,517,600 and the highest revenue forecast at $142,869,421,760.